

# Dirk Rades

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3938143/publications.pdf>

Version: 2024-02-01

283  
papers

3,821  
citations

218677

26  
h-index

189892

50  
g-index

283  
all docs

283  
docs citations

283  
times ranked

3876  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy with or without Decompressive Surgery for Metastatic Spinal Cord Compression: A Retrospective Matched-Pair Study Including Data from Prospectively Evaluated Patients. <i>Cancers</i> , 2022, 14, 1260.	3.7	7
2	Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer. <i>Anticancer Research</i> , 2022, 42, 1973-1977.	1.1	1
3	A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer. <i>Anticancer Research</i> , 2022, 42, 2029-2032.	1.1	1
4	Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1038-1052.	7.0	13
5	Risk Factors for Sleep Problems Prior to Radiochemotherapy for Malignant Gliomas. <i>In Vivo</i> , 2022, 36, 325-329.	1.3	4
6	Prognostic Factors of Survival After Radiotherapy for Lung Cancer—The Impact of Smoking Pack Years. <i>In Vivo</i> , 2022, 36, 1297-1301.	1.3	1
7	Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers. <i>Anticancer Research</i> , 2022, 42, 2657-2663.	1.1	6
8	Smoking-, Alcohol-, and Age-Related Alterations of Blood Monocyte Subsets and Circulating CD4/CD8 T Cells in Head and Neck Cancer. <i>Biology</i> , 2022, 11, 658.	2.8	6
9	Prognostic Value of Preclinical Markers after Radiotherapy of Metastatic Spinal Cord Compression—An Additional Analysis of Patients from Two Prospective Trials. <i>Cancers</i> , 2022, 14, 2547.	3.7	1
10	Palliative Radiotherapy of Primary Glioblastoma. <i>In Vivo</i> , 2021, 35, 483-487.	1.3	4
11	Comparison of Conventional Fractionation and Accelerated Fractionation With Concomitant Boost for Radiotherapy of Non-metastatic Stage IV Head-and-Neck Cancer. <i>In Vivo</i> , 2021, 35, 411-415.	1.3	10
12	A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme. <i>Anticancer Research</i> , 2021, 41, 379-384.	1.1	2
13	Comparison of 5 Gy and 10 Gy for metastatic spinal cord compression using data from three prospective trials. <i>Radiation Oncology</i> , 2021, 16, 7.	2.7	10
14	Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition. <i>Translational Lung Cancer Research</i> , 2021, 10, 1424-1443.	2.8	19
15	Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 2021, 8, 640515.	2.6	13
16	A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG). <i>BMC Cancer</i> , 2021, 21, 386.	2.6	6
17	Karnofsky Performance Score — An Independent Prognostic Factor of Survival After Palliative Irradiation for Sino-nasal Cancer. <i>Anticancer Research</i> , 2021, 41, 2495-2499.	1.1	3
18	Sleep Disorders in Patients With Breast Cancer Prior to a Course of Radiotherapy — Prevalence and Risk Factors. <i>Anticancer Research</i> , 2021, 41, 2489-2494.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Palliative Local Radiotherapy for Advanced Squamous Cell Carcinoma of the Head-and-Neck: Prognostic Factors of Survival. <i>Anticancer Research</i> , 2021, 41, 3205-3210.	1.1	0
20	A New Survival Score for Patients Scheduled for Palliative Irradiation of Locally Advanced Carcinoma of the Head-and-Neck. <i>Anticancer Research</i> , 2021, 41, 3055-3058.	1.1	2
21	Frequency and Risk Factors of Sleep Disturbances in Patients With Prostate Cancer Assigned to Local or Loco-regional Radiotherapy. <i>Anticancer Research</i> , 2021, 41, 5165-5169.	1.1	4
22	Sleep Disorders Prior to Adjuvant Radiation Therapy for Gynecological Malignancies. <i>Anticancer Research</i> , 2021, 41, 4407-4410.	1.1	4
23	Evaluation of Pre-radiotherapy Sleep Disorders in Patients With Rectal or Anal Cancer. <i>Anticancer Research</i> , 2021, 41, 4439-4442.	1.1	8
24	Risk Factors for Sleep Disturbances in Patients Scheduled for Radiotherapy of Head-and-Neck Cancer. <i>Anticancer Research</i> , 2021, 41, 5065-5069.	1.1	5
25	Sleep Disorders Before and During the COVID-19 Pandemic in Patients Assigned to Adjuvant Radiotherapy for Breast Cancer. <i>In Vivo</i> , 2021, 35, 2253-2260.	1.3	14
26	Accelerated Fractionation With Concomitant Boost vs. Conventional Radio-chemotherapy for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head-and-Neck (SCCHN). <i>Anticancer Research</i> , 2021, 41, 477-484.	1.1	6
27	Accelerated Fractionation Plus Chemotherapy <i>versus</i> Conventionally Fractionated Radiochemotherapy for Unresectable Head-and-Neck Cancer. <i>Anticancer Research</i> , 2021, 41, 877-884.	1.1	7
28	Palliative Radiotherapy for Cutaneous Squamous Cell Carcinoma of the Head-and-Neck Region. <i>In Vivo</i> , 2021, 35, 2283-2288.	1.3	4
29	Emotional Problems Prior to Adjuvant Radiation Therapy for Breast Cancer. <i>In Vivo</i> , 2021, 35, 2763-2770.	1.3	5
30	Sleep Disturbances in Lung Cancer Patients Assigned to Definitive or Adjuvant Irradiation. <i>In Vivo</i> , 2021, 35, 3333-3337.	1.3	5
31	Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas. <i>Frontiers in Oncology</i> , 2021, 11, 712788.	2.8	5
32	Wearable electroencephalography for ultra-long-term seizure monitoring: a systematic review and future prospects. <i>Expert Review of Medical Devices</i> , 2021, 18, 57-67.	2.8	11
33	Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database. <i>Translational Lung Cancer Research</i> , 2021, 10, 4250-4265.	2.8	11
34	A prospective interventional study investigating sleep disorders prior to and during adjuvant radiotherapy for breast cancer. <i>BMC Cancer</i> , 2021, 21, 1349.	2.6	1
35	A Simple Clinical Instrument to Predict the Survival Probability of Breast Cancer Patients Receiving Radiotherapy for Bone Metastases. <i>Anticancer Research</i> , 2020, 40, 367-371.	1.1	3
36	External Validation of a Survival Score for Limited-Stage Small Cell Lung Cancer Patients Treated with Chemoradiotherapy. <i>Lung</i> , 2020, 198, 201-206.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Precision Radiation Therapy for Metastatic Spinal Cord Compression: Final Results of the PRE-MODE Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 780-789.	0.8	18
38	An easy-to-use scoring system to estimate the survival of patients irradiated for bone metastases from lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1067-1073.	2.8	5
39	Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 1665-1668.	1.1	5
40	Estimating the Lifespan of Elderly Patients With Cerebral Metastases from Kidney Cancer. <i>In Vivo</i> , 2020, 34, 1321-1324.	1.3	2
41	The Results of Whole-brain Radiotherapy for Elderly Patients With Brain Metastases from Urinary Bladder Cancer. <i>In Vivo</i> , 2020, 34, 1317-1320.	1.3	1
42	Radiotherapy of Grade III Gliomas: Identification of Clinical Prognostic Factors for Local Tumor Control and Survival. <i>In Vivo</i> , 2020, 34, 3627-3630.	1.3	1
43	CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5508.	4.1	6
44	Pre-operative Seizures in Patients With Single Brain Metastasis Treated With Resection Plus Whole-Brain Irradiation and a Boost. <i>In Vivo</i> , 2020, 34, 2705-2709.	1.3	2
45	Development of a multivariable prediction model to estimate the remaining lifespan of elderly patients with cerebral metastases from small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1433-1440.	2.8	2
46	Pneumonitis after radiotherapy for lung cancer (PARALUC): an interventional study to create a symptom-based scoring system for identification of patients developing radiation pneumonitis. <i>BMC Cancer</i> , 2020, 20, 785.	2.6	5
47	A Simple Implement for Assessing the Survival of Elderly Patients With Melanoma Irradiated for Cerebral Metastases. <i>In Vivo</i> , 2020, 34, 1361-1364.	1.3	2
48	Predicting the Risk of Subsequent Distant Brain Metastases After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients. <i>Anticancer Research</i> , 2020, 40, 4081-4086.	1.1	0
49	Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM). <i>Anticancer Research</i> , 2020, 40, 7025-7030.	1.1	3
50	Re-Irradiation for Recurrent Glioblastoma Multiforme. <i>Anticancer Research</i> , 2020, 40, 7077-7081.	1.1	9
51	Clinical Prognostic Factors for Local Control and Survival After Irradiation of Grade II Gliomas. <i>In Vivo</i> , 2020, 34, 3719-3722.	1.3	2
52	Remaining Lifespan of Patients Aged ≥65 Years Receiving Whole-brain Irradiation for Metastases from Cancer of Unknown Primary. <i>Anticancer Research</i> , 2020, 40, 2261-2264.	1.1	3
53	Elderly Patients With Single Brain Metastasis – Overall Survival After Surgery Plus Whole-Brain Irradiation and a Radiation Boost. <i>In Vivo</i> , 2020, 34, 1421-1425.	1.3	1
54	Prognostic factors and outcome of reirradiation for locally recurrent small cell lung cancer – a multicenter study. <i>Translational Lung Cancer Research</i> , 2020, 9, 232-238.	2.8	7

#	ARTICLE	IF	CITATIONS
55	Radiotherapy-related skin toxicity (RAREST-02): A randomized trial testing the effect of a mobile application reminding head-and-neck cancer patients to perform skin care (reminder app) on radiation dermatitis. <i>Trials</i> , 2020, 21, 424.	1.6	13
56	Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a Randomized phase II trial (LEOPARD-2). <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 795-804.	2.0	9
57	A Scoring Tool to Estimate the Survival of Elderly Patients With Brain Metastases from Esophageal Cancer Receiving Whole-brain Irradiation. <i>Anticancer Research</i> , 2020, 40, 1661-1664.	1.1	1
58	Seizures Prior to Whole-brain Irradiation for Metastatic Disease: Prevalence, Risk Factors and Association With Survival. <i>Anticancer Research</i> , 2020, 40, 3429-3434.	1.1	1
59	Extra-cerebral Metastasis – An Independent Predictor of Survival in Older Patients With Brain Metastases Receiving a Local Therapy Plus Whole-Brain Radiotherapy (WBRT). <i>Anticancer Research</i> , 2020, 40, 2841-2845.	1.1	4
60	Interval Between Cancer Diagnosis and Radiotherapy – An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer. <i>In Vivo</i> , 2020, 34, 767-770.	1.3	1
61	Survival After Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiotherapy (FSRT) for Cerebral Metastases in the Elderly. <i>In Vivo</i> , 2020, 34, 1909-1913.	1.3	3
62	Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis. <i>Anticancer Research</i> , 2020, 40, 3961-3965.	1.1	5
63	Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer. <i>In Vivo</i> , 2020, 34, 679-682.	1.3	3
64	A Disease-specific Score for Estimating Survival After Irradiation of Bone Metastases from Colorectal Cancer. <i>Anticancer Research</i> , 2020, 40, 287-291.	1.1	1
65	EVII as a Marker for Lymph Node Metastasis in HNSCC. <i>International Journal of Molecular Sciences</i> , 2020, 21, 854.	4.1	19
66	Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast. <i>Anticancer Research</i> , 2020, 40, 2271-2274.	1.1	3
67	An Easy-To-Use Survival Score Compared to Existing Tools for Older Patients with Cerebral Metastases from Colorectal Cancer. <i>Cancers</i> , 2020, 12, 833.	3.7	5
68	An Instrument to Guide Physicians when Estimating the Survival of Elderly Patients With Brain Metastasis from Gynecological Cancer. <i>Anticancer Research</i> , 2020, 40, 2257-2260.	1.1	3
69	Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 2847-2851.	1.1	2
70	Occurrence of Seizures Prior to Single-fraction Radiosurgery or Multi-fraction Stereotactic Radiotherapy in Patients With Very Few Brain Metastases. <i>Anticancer Research</i> , 2020, 40, 3499-3504.	1.1	1
71	Pre-Treatment Seizures in Patients With 1-3 Cerebral Metastases Receiving Local Therapies Plus Whole-brain Radiotherapy. <i>In Vivo</i> , 2020, 34, 2727-2731.	1.3	2
72	Re-Evaluation of Prognostic Factors for Survival After Radiotherapy of Cerebral Gliomas: A Supplementary Analysis to a Previous Study. <i>Anticancer Research</i> , 2020, 40, 6513-6515.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Prognostic Role of Pre-Treatment Symptoms for Survival of Patients Irradiated for Brain Metastases. <i>Anticancer Research</i> , 2019, 39, 4273-4277.	1.1	4
74	Prevalence and Characteristics of Pneumonitis Following Irradiation of Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 6355-6358.	1.1	22
75	Prevalence of metastases within the hypothalamic-pituitary area in patients with brain metastases. <i>Radiation Oncology</i> , 2019, 14, 152.	2.7	8
76	Patient-Reported Outcomes—Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy $\times$ 5 to 3 Gy $\times$ 10 for Metastatic Epidural Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 760-764.	0.8	9
77	A randomized trial (RAREST-01) comparing Mepitel® Film and standard care for prevention of radiation dermatitis in patients irradiated for locally advanced squamous cell carcinoma of the head-and-neck (SCCHN). <i>Radiotherapy and Oncology</i> , 2019, 139, 79-82.	0.6	25
78	Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO). <i>Radiation Oncology</i> , 2019, 14, 3.	2.7	1
79	Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer. <i>Anticancer Research</i> , 2019, 39, 2569-2574.	1.1	4
80	Estimating Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Whole-brain Radiotherapy With a New Tool. <i>Anticancer Research</i> , 2019, 39, 2091-2095.	1.1	5
81	Subfoveal choriocapillaris, Sattler's and Haller's layer thickness predict clinical response to stereotactic radiotherapy in neovascular age-related macular degeneration patients. <i>Journal of Current Ophthalmology</i> , 2019, 31, 92-94.	0.8	3
82	Predictors of Outcomes and a Scoring System for Estimating Survival in Patients Treated With Radiotherapy for Metastatic Spinal Cord Compression From Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 322-329.	2.6	10
83	Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses. <i>Anticancer Research</i> , 2019, 39, 1343-1346.	1.1	4
84	Comparison of Diagnosis-specific Survival Scores for Patients With Cerebral Metastases from Malignant Melanoma Including the New WBRT-30-MM. <i>Anticancer Research</i> , 2019, 39, 1501-1505.	1.1	3
85	A New Diagnosis-Specific Survival Score for Patients to be Irradiated for Brain Metastases from Non-small Cell Lung Cancer. <i>Lung</i> , 2019, 197, 321-326.	3.3	9
86	Comparison of Diagnosis-Specific Survival Scores for Patients with Small-Cell Lung Cancer Irradiated for Brain Metastases. <i>Cancers</i> , 2019, 11, 233.	3.7	7
87	Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients. <i>Anticancer Research</i> , 2019, 39, 6217-6222.	1.1	3
88	Prognostic factors and a new scoring system for survival of patients irradiated for bone metastases. <i>BMC Cancer</i> , 2019, 19, 1156.	2.6	10
89	Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): a prospective multicenter study. <i>BMC Cancer</i> , 2019, 19, 1163.	2.6	14
90	Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma. <i>Melanoma Research</i> , 2019, 29, 187-195.	1.2	27

#	ARTICLE	IF	CITATIONS
91	Prevalence and Characteristics of Symptomatic Pneumonitis After Radiotherapy of Patients With Locally Advanced Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 6909-6913.	1.1	10
92	A New Phantom for Individual Verification of the Dose Distribution in Precision Radiotherapy for Head-and-Neck Cancer. <i>Anticancer Research</i> , 2019, 39, 6931-6938.	1.1	8
93	Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 129-136.	2.5	8
94	Epidural and intramedullary spinal metastasis: clinical features and role of fractionated radiotherapy. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 149, 227-238.	1.8	8
95	Radiotherapy related skin toxicity (RAREST-01): Mepitel <sup>®</sup> film versus standard care in patients with locally advanced head-and-neck cancer. <i>BMC Cancer</i> , 2018, 18, 197.	2.6	10
96	Rotating Gamma System Irradiation: A Promising Treatment for Low-grade Brainstem Gliomas. <i>In Vivo</i> , 2018, 31, 957-960.	1.3	6
97	A scoring system to predict local progression-free survival in patients irradiated with 20 Gy in 5 fractions for malignant spinal cord compression. <i>Radiation Oncology</i> , 2018, 13, 257.	2.7	3
98	Potential Prognostic Factors of Downstaging Following Preoperative Chemoradiation for High Rectal Cancer. <i>In Vivo</i> , 2018, 32, 1481-1484.	1.3	4
99	Prognostic Factors and a Survival Score in Patients Irradiated for Metastatic Epidural Spinal Cord Compression from Urothelial Carcinoma Cancer of the Bladder. <i>Anticancer Research</i> , 2018, 38, 6841-6846.	1.1	3
100	A Matched-Pair Study Comparing Surgery Plus Neoadjuvant Radio-Chemotherapy and Surgery Alone for High Rectal Cancers. <i>Anticancer Research</i> , 2018, 38, 6877-6880.	1.1	6
101	Whole-Brain Radiotherapy (WBRT) for Brain Metastases: Does the Interval Between Imaging and Treatment Matter?. <i>Anticancer Research</i> , 2018, 38, 6835-6840.	1.1	6
102	Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 6897-6903.	1.1	4
103	Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis. <i>Frontiers in Immunology</i> , 2018, 9, 2262.	4.8	20
104	Role of Neoadjuvant Radio-chemotherapy for the Treatment of High Rectal Cancer. <i>Anticancer Research</i> , 2018, 38, 5371-5377.	1.1	6
105	Preliminary Results from a Prospective Study Comparing White Blood Cell and Neutrophil Counts from a Laboratory to Those Measured with a New Device in Patients with Breast Cancer. <i>In Vivo</i> , 2018, 32, 1283-1288.	1.3	11
106	A Specific Survival Score for Patients Receiving Local Therapy for Single Brain Metastasis from a Gynecological Malignancy. <i>In Vivo</i> , 2018, 32, 825-828.	1.3	16
107	Predicting the Ambulatory Status of Patients Irradiated for Metastatic Spinal Cord Compression (MSCC) from Head-and-neck Cancer. <i>Anticancer Research</i> , 2018, 38, 4833-4837.	1.1	4
108	A Tool to Predict the Probability of Intracerebral Recurrence or New Cerebral Metastases After Whole-brain Irradiation in Patients with Head-and-Neck Cancer. <i>Anticancer Research</i> , 2018, 38, 4199-4202.	1.1	11

#	ARTICLE	IF	CITATIONS
109	1x8 Gy versus 5x4 Gy for metastatic epidural spinal cord compression: a matched-pair study of three prognostic patient subgroups. <i>Radiation Oncology</i> , 2018, 13, 21.	2.7	10
110	Analysis of predictors of pain response in patients with bone metastasis undergoing palliative radiotherapy: Does age matter?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 578-584.	1.8	6
111	Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 3231-3242.	1.1	18
112	An Instrument for Estimating the 6-Month Survival Probability After Whole-brain Irradiation Alone for Cerebral Metastases from Gynecological Cancer. <i>Anticancer Research</i> , 2018, 38, 3753-3756.	1.1	13
113	Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with 42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer. <i>Anticancer Research</i> , 2018, 38, 3653-3656.	1.1	4
114	Inhibition of GSK3 $\beta$ /I $\kappa$ B impairs the progression of HNSCC. <i>Oncotarget</i> , 2018, 9, 27630-27644.	1.8	7
115	Stereotactic Radiosurgery Alone for One to Two Brain Metastases from Cancer of Unknown Primary. <i>Anticancer Research</i> , 2018, 38, 565-567.	1.1	6
116	Predictive Factors for Local Control and Survival in Patients with Cancer of Unknown Primary (CUP) Irradiated for Cerebral Metastases. <i>Anticancer Research</i> , 2018, 38, 2415-2418.	1.1	6
117	Karnofsky Performance Score Is Predictive of Survival After Palliative Irradiation of Metastatic Bile Duct Cancer.. <i>Anticancer Research</i> , 2018, 37, 949-951.	1.1	7
118	Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. <i>Anticancer Research</i> , 2018, 38, 1009-1015.	1.1	3
119	Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible. <i>Anticancer Research</i> , 2018, 38, 519-523.	1.1	0
120	Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases. <i>In Vivo</i> , 2018, 32, 381-384.	1.3	9
121	A New Scoring-system for Estimating Overall Survival After Radiotherapy of Recurrent Head and Neck Cancers. <i>Anticancer Research</i> , 2018, 38, 1611-1613.	1.1	0
122	Predicting Survival After Whole-brain Irradiation for Cerebral Metastases in Patients with Cancer of the Bladder. <i>In Vivo</i> , 2018, 32, 633-636.	1.3	5
123	Predicting the Risk of Developing New Cerebral Lesions After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastases from Renal Cell Carcinoma. <i>Anticancer Research</i> , 2018, 38, 2973-2976.	1.1	4
124	A Score to Identify Patients with Brain Metastases from Colorectal Cancer Who May Benefit from Whole-brain Radiotherapy in Addition to Stereotactic Radiosurgery/Radiotherapy. <i>Anticancer Research</i> , 2018, 38, 3111-3114.	1.1	5
125	A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases. <i>BMC Cancer</i> , 2017, 17, 30.	2.6	9
126	The Leukotriene B4 and its Receptor BLT1 Are Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1104-1113.	0.7	73



#	ARTICLE	IF	CITATIONS
127	Neutrophil-to-Lymphocyte Ratio Predicts Outcome in Limited Disease Small-cell Lung Cancer. <i>Lung</i> , 2017, 195, 217-224.	3.3	35
128	Changes in Peripapillary Nerve Fiber Layer Thickness after Adjuvant Stereotactic Radiotherapy in Patients with Neovascular Age-Related Macular Degeneration. <i>Current Eye Research</i> , 2017, 42, 1698-1706.	1.5	1
129	A New Scoring Tool to Assess Overall Survival in Patients With Intracerebral Metastases From Gynecological Cancers. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 597-602.	2.5	8
130	A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases. <i>Radiation Oncology</i> , 2017, 12, 69.	2.7	14
131	The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix Versus Paracrine Factors. <i>Translational Oncology</i> , 2017, 10, 578-588.	3.7	39
132	Role of the overall treatment time of radiotherapy with 10 Gy for outcomes in patients with metastatic spinal cord compression. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 388-393.	1.8	1
133	Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1021-1027.	1.6	13
134	Results of a multicenter study investigating the potential impact of the overall treatment time on outcomes of radiation therapy alone with 5 Gy for metastatic epidural spinal cord compression. <i>Practical Radiation Oncology</i> , 2017, 7, 137-144.	2.1	3
135	High-precision radiotherapy of motor deficits due to metastatic spinal cord compression (PRE-MODE): a multicenter phase 2 study. <i>BMC Cancer</i> , 2017, 17, 818.	2.6	5
136	Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, 732-738.	2.5	22
137	Survival Following Palliative External-beam Radiotherapy of Locally Advanced and Metastatic Liver Cancer. <i>Anticancer Research</i> , 2017, 37, 203-206.	1.1	2
138	Development of a Survival Score for Patients with Cerebral Metastases from Melanoma. <i>Anticancer Research</i> , 2017, 37, 249-252.	1.1	6
139	Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 1485-1488.	1.1	6
140	Prognostic Factors and Treatment of Earlystage Small-cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 1535-1538.	1.1	8
141	Simplified Comorbidity Score and Eastern Cooperative Oncology Group Performance Score Predicts Survival in Patients Receiving Organ-preserving Treatment for Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 2693-2696.	1.1	14
142	Phase I Study of Definitive Radio-chemotherapy with Cisplatin, 5-Fluorouracil and Cetuximab for Unresectable Locally Advanced Esophageal Cancer. <i>Anticancer Research</i> , 2017, 37, 2703-2708.	1.1	2
143	A Scoring System to Predict the Development of Bone Metastasis After Radical Resection of Colorectal Cancer. <i>Anticancer Research</i> , 2017, 37, 5169-5172.	1.1	11
144	Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients. <i>In Vivo</i> , 2017, 31, 239-242.	1.3	5

#	ARTICLE	IF	CITATIONS
145	Factors Impacting the Overall Survival of Patients Irradiated for Invasive Carcinoma of the Urinary Bladder. <i>In Vivo</i> , 2017, 31, 741-744.	1.3	4
146	Clinical Factors Associated with Treatment Outcomes following Whole-brain Irradiation in Patients with Prostate Cancer. <i>In Vivo</i> , 2017, 31, 35-38.	1.3	4
147	Outcomes After Radio(chemo)therapy for Non-Metastatic Bile Duct Cancer. <i>In Vivo</i> , 2017, 31, 117-120.	1.3	1
148	A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 1481-1484.	1.1	5
149	A New Prognostic Instrument Specifically Designed for Patients Irradiated for Recurrent Carcinoma of the Bladder. <i>In Vivo</i> , 2017, 31, 435-438.	1.3	3
150	Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly. <i>Anticancer Research</i> , 2017, 37, 3287-3290.	1.1	4
151	Validation of a Score Developed to Estimate the 6-month Survival of Patients Treated with Palliative Local Radiotherapy for Advanced Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 2537-2540.	1.1	0
152	A New Prognostic Tool for Patients Undergoing Radiotherapy plus Upfront Transurethral Resection for Bladder Cancer. <i>In Vivo</i> , 2017, 31, 745-748.	1.3	5
153	A Survival Score Based on Symptoms and Performance Status for Patients with High-grade Gliomas Receiving Radiochemotherapy. <i>In Vivo</i> , 2017, 31, 689-693.	1.3	3
154	Radiosurgery with a Rotating Gamma System: A Very Effective Treatment for Symptomatic Cerebral Cavernomas. <i>Anticancer Research</i> , 2017, 37, 3729-3733.	1.1	3
155	Predictive Factors and a Survival Score for Patients Irradiated for Metastatic Spinal Cord Compression from Carcinoma of the Salivary Glands. <i>Anticancer Research</i> , 2017, 37, 7011-7015.	1.1	3
156	Conformal 3D planned radiotherapy for pelvic lymphoceles following surgery for urological cancer: A case study. <i>Molecular and Clinical Oncology</i> , 2016, 5, 342-344.	1.0	2
157	Excellent outcomes after radiotherapy alone for malignant spinal cord compression from myeloma. <i>Radiology and Oncology</i> , 2016, 50, 337-340.	1.7	21
158	Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?. <i>Oral Oncology</i> , 2016, 57, 40-45.	1.5	11
159	A New Score for Estimating Survival After Definitive Radiochemotherapy of Limited Disease Small Cell Lung Cancers. <i>Lung</i> , 2016, 194, 625-629.	3.3	7
160	Hyperglycemia in Stroke Impairs Polarization of Monocytes/Macrophages to a Protective Noninflammatory Cell Type. <i>Journal of Neuroscience</i> , 2016, 36, 9313-9325.	3.6	39
161	The effect of low hemoglobin levels on outcomes of radiotherapy following microscopically complete resection of locally advanced SCCFN: Implications for the future. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1441-1444.	1.7	4
162	Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1436-1440.	1.7	4

#	ARTICLE	IF	CITATIONS
163	Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20 mg/m <sup>2</sup> cisplatin on five days every four weeks an alternative to 100 mg/m <sup>2</sup> cisplatin every three weeks?. <i>Oral Oncology</i> , 2016, 59, 67-72.	1.5	13
164	Best supportive care â€” a reasonable option for patients with brain metastases?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 722-724.	27.6	0
165	Comparison of weekly administration of cisplatin versus three courses of cisplatin 100Âmg/m <sup>2</sup> for definitive radiochemotherapy of locally advanced head-and-neck cancers. <i>BMC Cancer</i> , 2016, 16, 437.	2.6	22
166	A scoring system for predicting the survival prognosis of patients receiving stereotactic body radiation therapy (SBRT) for 1â€“3 lung metastases. <i>Lung</i> , 2016, 194, 631-635.	3.3	4
167	A Survival Score for Patients Receiving Palliative Irradiation for Locally Advanced Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 558-562.	2.6	11
168	A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression. <i>BMC Cancer</i> , 2016, 16, 292.	2.6	7
169	A Prognostic Instrument to Estimate the Survival of Elderly Patients Irradiated for Metastatic Epidural Spinal Cord Compression From Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 279-284.	2.6	6
170	Value of Comorbidity Scales for Predicting Survival After Radiochemotherapy of Small Cell Lung Cancer. <i>Lung</i> , 2016, 194, 295-298.	3.3	8
171	Stereotactic Body Radiotherapy (SBRT) with Lower Doses for Selected Patients with Stage I Non-small-cell Lung Cancer (NSCLC). <i>Lung</i> , 2016, 194, 291-294.	3.3	15
172	Radiotherapy With 4 Gy Ã— 5 Versus 3 Gy Ã— 10 for Metastatic Epidural Spinal Cord Compression: Final Results of the SCORE-2 Trial (ARO 2009/01). <i>Journal of Clinical Oncology</i> , 2016, 34, 597-602.	1.6	105
173	Prognostic Factors for Survival in Patients Treated with Multimodal Therapy for Anaplastic Thyroid Cancer. <i>Anticancer Research</i> , 2016, 36, 4697-4700.	1.1	15
174	Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers. <i>Anticancer Research</i> , 2016, 36, 4777-4780.	1.1	3
175	Overall Survival After Whole-Brain Radiation Therapy for Intracerebral Metastases from Testicular Cancer. <i>Anticancer Research</i> , 2016, 36, 4817-4820.	1.1	2
176	A Scoring Instrument to Predict the Survival Prognoses of Patients with Metastatic Epidural Spinal Cord Compression from Gynecological Malignancies. <i>Anticancer Research</i> , 2016, 36, 5469-5472.	1.1	5
177	Predicting Survival After Irradiation of Metastases from Transitional Carcinoma of the Bladder. <i>Anticancer Research</i> , 2016, 36, 6663-6666.	1.1	11
178	Comparison of 20Ã—2 Gy and 12Ã—3 Gy for Whole-brain Irradiation of Multiple Brain Metastases from Malignant Melanoma. <i>In Vivo</i> , 2016, 30, 917-920.	1.3	7
179	Outcomes After Whole-brain Radiotherapy for Brain Metastases with 5Ã—4 Gy: Importance of Overall Treatment Time. <i>Anticancer Research</i> , 2016, 36, 4941-4946.	1.1	1
180	Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck. <i>Anticancer Research</i> , 2016, 36, 5463-5468.	1.1	5

#	ARTICLE	IF	CITATIONS
181	Prognostic Factors After Whole-brain Radiotherapy Alone for Brain Metastases from Malignant Melanoma. <i>Anticancer Research</i> , 2016, 36, 6637-6640.	1.1	3
182	Prognostic Factors in Patients Irradiated for Recurrent Head-and-Neck Cancer. <i>Anticancer Research</i> , 2016, 36, 6547-6550.	1.1	2
183	Personalized Radiotherapeutic Approaches for Elderly Patients with Epidural Cord Compression from Gastric Cancer. <i>In Vivo</i> , 2016, 30, 69-72.	1.3	2
184	Immunoglobulin G (IgG) Subtype Is Associated with a Favorable Survival Prognosis in Patients Irradiated for Spinal Cord Compression from Myeloma. <i>Anticancer Research</i> , 2016, 36, 375-8.	1.1	0
185	Estimating the Survival of Elderly Patients with Renal Cell Carcinoma Presenting with Malignant Spinal Cord Compression. <i>Anticancer Research</i> , 2016, 36, 409-13.	1.1	1
186	Karnosky Performance Score and Radiation Dose Predict Survival of Patients Re-irradiated for a Locoregional Recurrence of Small Cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 803-5.	1.1	4
187	Stereotactic Body Radiation Therapy (SBRT) for Recurrent Non-small Cell Lung Cancer (NSCLC). <i>Anticancer Research</i> , 2016, 36, 825-8.	1.1	7
188	Stereotactic Body Radiotherapy Provides Excellent Long-Term Local Control of Very Few Lung Metastases. <i>In Vivo</i> , 2016, 30, 155-7.	1.3	1
189	A Survival Score for Patients Receiving Stereotactic Radiosurgery Alone for Brain Metastases from Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 1073-6.	1.1	5
190	Impact of the Radiation Dose on Survival after Radiochemotherapy for Small-cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 1089-91.	1.1	0
191	Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 1825-8.	1.1	7
192	Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly. <i>Anticancer Research</i> , 2016, 36, 1829-33.	1.1	2
193	Outcomes After Irradiation of Epidural Spinal Cord Compression Due to Metastatic Thyroid Cancer. <i>Anticancer Research</i> , 2016, 36, 2035-9.	1.1	6
194	Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer. <i>Anticancer Research</i> , 2016, 36, 2487-91.	1.1	1
195	Hypofractionated Radiotherapy for Breast Cancer Including Risk-adapted Boost: Update on Tolerance and Efficacy of an Accelerated START A Regime. <i>Anticancer Research</i> , 2016, 36, 2513-22.	1.1	1
196	Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer. <i>Anticancer Research</i> , 2016, 36, 2523-6.	1.1	2
197	A Total Radiation Dose of 70 Gy Is Required After Macroscopically Incomplete Resection of Squamous Cell Carcinoma of the Head and Neck. <i>Anticancer Research</i> , 2016, 36, 2989-92.	1.1	3
198	Potential Impact of the Overall Treatment Time on Outcomes after Whole-brain Irradiation with 10Å–3 Gy for Brain Metastases. <i>Anticancer Research</i> , 2016, 36, 3071-4.	1.1	1

#	ARTICLE	IF	CITATIONS
199	Radiation Therapy Alone Provides Excellent Outcomes for Spinal Cord Compression from Vertebral Lymphoma. <i>Anticancer Research</i> , 2016, 36, 3081-3.	1.1	5
200	Prognostic Factors Including the Expression of Thyroid Transcription Factor 1 (TTF1) in Patients Irradiated for Limited-disease Small Cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 3499-503.	1.1	7
201	Palliative Radiation Therapy for Spinal Cord Compression from Metastatic Soft Tissue Sarcoma. <i>In Vivo</i> , 2016, 30, 529-31.	1.3	6
202	Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer. <i>Anticancer Research</i> , 2016, 36, 4177-80.	1.1	7
203	Prognosis of Patients with Metastatic Spinal Cord Compression from Adrenocortical Carcinoma. <i>In Vivo</i> , 2016, 30, 717-9.	1.3	2
204	Nipple-sparing mastectomy in breast cancer patients: The role of adjuvant radiotherapy (Review). <i>Oncology Letters</i> , 2015, 9, 2435-2441.	1.8	17
205	A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. <i>Radiation Oncology</i> , 2015, 10, 173.	2.7	11
206	A new instrument for estimating the survival of patients with metastatic epidural spinal cord compression from esophageal cancer. <i>Radiology and Oncology</i> , 2015, 49, 86-90.	1.7	5
207	Number of cerebral lesions predicts freedom from new brain metastases after radiosurgery alone in lung cancer patients. <i>Oncology Letters</i> , 2015, 10, 1109-1112.	1.8	5
208	Predicting the survival probability of gastric cancer patients developing metastatic epidural spinal cord compression (MESCC). <i>Gastric Cancer</i> , 2015, 18, 881-884.	5.3	5
209	A New Tool Predicting Survival After Radiosurgery Alone for One or Two Cerebral Metastases from Lung Cancer. <i>Lung</i> , 2015, 193, 299-302.	3.3	7
210	A matched-pair analysis comparing 5x4 Gy and 10x3 Gy for metastatic spinal cord compression (MSCC) in patients with favorable survival prognoses. <i>Radiation Oncology</i> , 2015, 10, 90.	2.7	2
211	Radiosensitive Hematopoietic Cells Determine the Extent of Skin Inflammation in Experimental Epidermolysis Bullosa Acquisita. <i>Journal of Immunology</i> , 2015, 195, 1945-1954.	0.8	30
212	A New Tool to Predict Survival after Radiosurgery Alone for Newly Diagnosed Cerebral Metastases. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 2967-2970.	1.2	8
213	International survey of the treatment of metastatic spinal cord compression. <i>Journal of Radiosurgery and SBRT</i> , 2015, 3, 237-245.	0.2	4
214	Radiosurgery with 20 Gy provides better local control of 1-3 brain metastases from breast cancer than with lower doses. <i>Anticancer Research</i> , 2015, 35, 333-6.	1.1	13
215	Predicting survival of patients with metastatic epidural spinal cord compression from cancer of the head-and-neck. <i>Anticancer Research</i> , 2015, 35, 385-8.	1.1	3
216	Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. <i>Anticancer Research</i> , 2015, 35, 3571-4.	1.1	13

#	ARTICLE	IF	CITATIONS
217	Predicting Survival After Irradiation of Metastases from Pancreatic Cancer. <i>Anticancer Research</i> , 2015, 35, 4105-8.	1.1	5
218	Prophylactic Radiotherapy to Intervention Sites in Malignant Pleural Mesothelioma--Single-institution Experience and Literature Review. <i>Anticancer Research</i> , 2015, 35, 4151-4.	1.1	3
219	Estimation of the Six-month Survival Probability After Radiosurgery for Brain Metastases from Kidney Cancer. <i>Anticancer Research</i> , 2015, 35, 4215-7.	1.1	10
220	Predicting Survival After Irradiation for Brain Metastases from Head and Neck Cancer. <i>In Vivo</i> , 2015, 29, 525-8.	1.3	6
221	A New Predictive Tool for Optimization of the Treatment of Brain Metastases from Colorectal Cancer After Stereotactic Radiosurgery. <i>Anticancer Research</i> , 2015, 35, 5515-8.	1.1	5
222	Defining the Optimal Dose of Stereotactic Radiosurgery for Treating Cerebral Metastases in Elderly Patients. <i>Anticancer Research</i> , 2015, 35, 5701-4.	1.1	0
223	Primary Breast Cancer with Synchronous Metastatic Disease - Indications for Local Radiotherapy to the Breast and Chest Wall. <i>Anticancer Research</i> , 2015, 35, 5807-12.	1.1	3
224	Metastatic Spinal Cord Compression: A Survival Score Particularly Developed for Elderly Prostate Cancer Patients. <i>Anticancer Research</i> , 2015, 35, 6189-92.	1.1	6
225	A Tool to Estimate Survival of Elderly Patients Presenting with Metastatic Epidural Spinal Cord Compression (MESCC) from Cancer of Unknown Primary. <i>Anticancer Research</i> , 2015, 35, 6219-22.	1.1	3
226	Radiation Therapy for Metastatic Spinal Cord Compression in Patients with Hepatocellular Carcinoma. <i>In Vivo</i> , 2015, 29, 749-52.	1.3	7
227	Predicting the Risk of New Cerebral Lesions After Stereotactic Radiosurgery (SRS) for Brain Metastases from Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 6793-7.	1.1	4
228	Do patients with very few brain metastases from breast cancer benefit from whole-brain radiotherapy in addition to radiosurgery?. <i>Radiation Oncology</i> , 2014, 9, 267.	2.7	6
229	Radiosurgery alone versus radiosurgery plus whole-brain irradiation for very few cerebral metastases from lung cancer. <i>BMC Cancer</i> , 2014, 14, 931.	2.6	7
230	A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone. <i>Radiation Oncology</i> , 2014, 9, 215.	2.7	21
231	Prognostic role of the number of involved extraspinal organs in patients with metastatic spinal cord compression. <i>Clinical Neurology and Neurosurgery</i> , 2014, 118, 12-15.	1.4	14
232	A validated score estimating ambulatory status following radiotherapy of elderly patients for metastatic spinal cord compression. <i>BMC Cancer</i> , 2014, 14, 589.	2.6	7
233	Stereotactic radiosurgery for newly diagnosed brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 786-791.	2.0	12
234	Metastatic spinal cord compression. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 919-924.	2.0	9

#	ARTICLE	IF	CITATIONS
235	LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer (LAEC).. Journal of Clinical Oncology, 2014, 32, 4081-4081.	1.6	9
236	Number of extraspinal organs with metastases: a prognostic factor of survival in patients with metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC). Anticancer Research, 2014, 34, 2503-7.	1.1	9
237	Re-irradiation of spinal cord compression due to metastasis in elderly patients. Anticancer Research, 2014, 34, 2555-8.	1.1	5
238	Metastatic spinal cord compression from pancreatic cancer. Anticancer Research, 2014, 34, 3727-30.	1.1	5
239	Biologic factors associated with tumor oxygenation are prognostic in patients with stage III esophageal cancer: long-term results. Anticancer Research, 2014, 34, 4351-5.	1.1	1
240	Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. Anticancer Research, 2014, 34, 5079-82.	1.1	9
241	Prognostic role of vascular endothelial growth factor and its receptor-1 in patients with esophageal cancer. Anticancer Research, 2014, 34, 5221-6.	1.1	3
242	Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. Anticancer Research, 2014, 34, 5589-92.	1.1	5
243	Predicting overall survival in patients with brain metastases from esophageal cancer. Anticancer Research, 2014, 34, 6763-5.	1.1	7
244	Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer. Anticancer Research, 2014, 34, 7309-13.	1.1	4
245	A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiotherapy and Oncology, 2013, 108, 123-127.	0.6	36
246	The first survival score for patients with brain metastases from small cell lung cancer (SCLC). Clinical Neurology and Neurosurgery, 2013, 115, 2029-2032.	1.4	21
247	A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care. Cancer, 2013, 119, 897-903.	4.1	54
248	Fibroblast Growth Factor 2â€”A Predictor of Outcome for Patients Irradiated for Stage II-III Nonâ€”Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 442-447.	0.8	17
249	Single brain metastasis: Resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery. Clinical Neurology and Neurosurgery, 2012, 114, 326-330.	1.4	20
250	A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer, 2012, 12, 302.	2.6	41
251	Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Practical Radiation Oncology, 2012, 2, 210-225.	2.1	516
252	Single brain metastasis: Radiosurgery alone compared with radiosurgery plus upâ€”front wholeâ€”brain radiotherapy. Cancer, 2012, 118, 2980-2985.	4.1	19

#	ARTICLE	IF	CITATIONS
253	Dose escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. <i>Cancer</i> , 2012, 118, 3852-3859.	4.1	38
254	The prognostic impact of tumor cell expression of estrogen receptor-1, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. <i>Cancer</i> , 2012, 118, 157-163.	4.1	46
255	Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection. <i>Cancer</i> , 2012, 118, 1138-1144.	4.1	19
256	Radiochemotherapy versus surgery plus radio(chemo)therapy for stage T3/T4 larynx and hypopharynx cancer – Results of a matched-pair analysis. <i>European Journal of Cancer</i> , 2011, 47, 2729-2734.	2.8	32
257	Surgery Followed by Radiotherapy Versus Radiotherapy Alone for Metastatic Spinal Cord Compression From Unfavorable Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e861-e868.	0.8	78
258	Radiation Therapy for Metastatic Disease. <i>Medical Radiology</i> , 2011, , 561-573.	0.1	2
259	Prognostic Impact of Erythropoietin Expression and Erythropoietin Receptor Expression on Locoregional Control and Survival of Patients Irradiated for Stage II/III Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 499-505.	0.8	14
260	Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 626-632.	2.0	36
261	Comparison of radiochemotherapy alone to surgery plus radio(chemo)therapy for non-metastatic stage III/IV squamous cell carcinoma of the head and neck. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 541-547.	2.0	16
262	Dose escalation of radiotherapy for Metastatic Spinal Cord Compression (MSCC) in patients with relatively favorable survival prognosis. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 729-735.	2.0	74
263	Final Results of a Prospective Study Comparing the Local Control of Short-Course and Long-Course Radiotherapy for Metastatic Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 524-530.	0.8	184
264	Scoring Systems to Estimate Intracerebral Control and Survival Rates of Patients Irradiated for Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1122-1127.	0.8	54
265	Comparison of Four Cisplatin-Based Radiochemotherapy Regimens for Nonmetastatic Stage III/IV Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1037-1044.	0.8	35
266	Dose Escalation for Metastatic Spinal Cord Compression in Patients With Relatively Radioresistant Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1492-1497.	0.8	28
267	Radiotherapeutic Options for Symptom Control in Breast Cancer. <i>Breast Care</i> , 2011, 6, 14-19.	1.4	8
268	Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC). <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 307-314.	2.0	14
269	Radiolabeled Cetuximab plus Whole-Brain Irradiation (WBI) for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer (NSCLC). <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 458-462.	2.0	25
270	Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis. <i>Oral Oncology</i> , 2010, 46, 549-552.	1.5	5



#	ARTICLE	IF	CITATIONS
271	The role of postoperative radiotherapy for the treatment of gangliogliomas. <i>Cancer</i> , 2010, 116, 432-442.	4.1	64
272	Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. <i>Cancer</i> , 2010, 116, 3670-3673.	4.1	85
273	Reply to the Role of postoperative radiotherapy for the treatment of gangliogliomas. <i>Cancer</i> , 2010, 116, 3071-3072.	4.1	1
274	Hypofractionated Whole-Brain Radiotherapy for Multiple Brain Metastases From Transitional Cell Carcinoma of the Bladder. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 404-408.	0.8	11
275	Dose-Fractionation Schedules for Radiotherapy of Bone Metastases. <i>Breast Care</i> , 2010, 5, 339-344.	1.4	5
276	Treatment of painful bone metastases. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 220-229.	27.6	60
277	The role of radiotherapy for metastatic epidural spinal cord compression. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 590-598.	27.6	111
278	Prognostic factors for survival and intracerebral control after irradiation for brain metastases from gynecological cancer. <i>Gynecologic Oncology</i> , 2009, 114, 506-508.	1.4	8
279	Radioactive EGFR Antibody Cetuximab in Multimodal Cancer Treatment: Stability and Synergistic Effects With Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1226-1231.	0.8	22
280	Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 198-205.	2.0	30
281	A New Scoring System to Predicting the Survival of Patients Treated with Whole-Brain Radiotherapy for Brain Metastases. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 251-255.	2.0	102
282	Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. <i>Cancer</i> , 2007, 110, 1345-1350.	4.1	41
283	Reduction of Overall Treatment Time in Patients Irradiated for More Than Three Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1509-1513.	0.8	42